Drug Delivery by Soft Matter

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (20 October 2020) | Viewed by 8066

Special Issue Editor


E-Mail
Guest Editor
Department of Chemical and Life Sciences Engineering, Virginia Commonwealth University, Richmond, VA 23219, USA
Interests: pharmaceuticals processing using soft matter; drug delivery; controlled release; nanoemulsions; hydrogels; polymeric micro/nanoparticles
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There is a burgeoning interest in the use of soft matter in pharmaceutical applications (e.g., the delivery of any type of drug) because of its potential. Soft matter systems encompass a wide range of materials, such as polymers, colloids, micro- or nano-emulsions, organogels, micelles, liposomes, etc., whose properties arise from the interplay of processes across multiple scales and phases. They have been widely used to solve many biomedical and pharmaceutical problems. In fact, they make it possible to overcome difficulties in the formulation and delivery of poorly water-soluble drug molecules such as solubility and bioavailability issues; they can settle some biological stability issues of protein- and peptide-based drugs; they can aid the design parenteral controlled release forms; and can provide functionalized soft matter nanocarriers that are very effective in drug targeting. 

The aim of this Special Issue of Pharmaceutics is to highlight and discuss the current progress in the use of soft matter systems for the encapsulation and delivery of both small and large therapeutic molecules. We welcome articles dealing with all aspects of the design and development of drug carriers utilizing soft matter principles, the understanding of their physicochemical properties, and their structure–properties–performance relations in drug delivery applications. All researchers working in these areas are cordially invited to publish their original research papers, brief communication reports, and review articles showcasing their expert opinions and perspectives.  

Dr. Abu Zayed Md Badruddoza
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • soft matter
  • polymers
  • colloids
  • micro or nano-emulsions
  • organogels
  • micelles
  • liposomes

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2175 KiB  
Article
Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
by Blerina Shkodra, Adrian T. Press, Antje Vollrath, Ivo Nischang, Stephanie Schubert, Stephanie Hoeppener, Dorothee Haas, Christoph Enzensperger, Marc Lehmann, Petra Babic, Kay Jovana Benecke, Anja Traeger, Michael Bauer and Ulrich S. Schubert
Pharmaceutics 2020, 12(11), 1110; https://doi.org/10.3390/pharmaceutics12111110 - 18 Nov 2020
Cited by 6 | Viewed by 3279
Abstract
Bisindolylmaleimide I (BIM-I) is a competitive pan protein kinase C inhibitor with anti-inflammatory and anti-metastatic properties, suggested to treat inflammatory diseases and various cancer entities. However, despite its therapeutic potential, BIM-I has two major drawbacks, i.e., it has a poor water solubility, and [...] Read more.
Bisindolylmaleimide I (BIM-I) is a competitive pan protein kinase C inhibitor with anti-inflammatory and anti-metastatic properties, suggested to treat inflammatory diseases and various cancer entities. However, despite its therapeutic potential, BIM-I has two major drawbacks, i.e., it has a poor water solubility, and it binds the human ether-à-go-go-related gene (hERG) ion channels, potentially causing deadly arrhythmias. In this case, a targeted delivery of BIM-I is imperative to minimize peripheral side effects. To circumvent these drawbacks BIM-I was encapsulated into nanoparticles prepared from poly(lactic-co-glycolic acid) (PLGA) functionalized by the near-infrared dye DY-635. DY-635 served as an active targeting moiety since it selectively binds the OATP1B1 and OATP1B3 transporters that are highly expressed in liver and cancer cells. PLGA-DY-635 (BIM-I) nanoparticles were produced by nanoprecipitation and characterized using dynamic light scattering, analytical ultracentrifugation, and cryogenic transmission electron microscopy. Particle sizes were found to be in the range of 20 to 70 nm, while a difference in sizes between the drug-loaded and unloaded particles was observed by all analytical techniques. In vitro studies demonstrated that PLGA-DY-635 (BIM-I) NPs prevent the PKC activation efficiently, proving the efficacy of the inhibitor after its encapsulation, and suggesting that BIM-I is released from the PLGA-NPs. Ultimately, our results present a feasible formulation strategy that improved the cytotoxicity profile of BIM-I and showed a high cellular uptake in the liver as demonstrated in vivo by intravital microscopy investigations. Full article
(This article belongs to the Special Issue Drug Delivery by Soft Matter)
Show Figures

Graphical abstract

12 pages, 2263 KiB  
Article
Nano-Vesicle Based Anti-Fungal Formulation Shows Higher Stability, Skin Diffusion, Biosafety and Anti-Fungal Efficacy In Vitro
by Isaac G. Deaguero, Md Nurul Huda, Victor Rodriguez, Jade Zicari, Taslim A. Al-Hilal, Abu Zayed Md Badruddoza and Md Nurunnabi
Pharmaceutics 2020, 12(6), 516; https://doi.org/10.3390/pharmaceutics12060516 - 05 Jun 2020
Cited by 14 | Viewed by 4345
Abstract
Opportunistic fungal infections are responsible for over 1.5 million deaths per year. This has created a need for highly effective antifungal medication to be as potent as possible. In this study, we improved the efficacy of a common over the counter (OTC) antifungal [...] Read more.
Opportunistic fungal infections are responsible for over 1.5 million deaths per year. This has created a need for highly effective antifungal medication to be as potent as possible. In this study, we improved the efficacy of a common over the counter (OTC) antifungal skin medication, miconazole, by encapsulating nano-molecules of the drug in cholesterol/sodium oleate nano-vesicles. These nano-vesicles were characterized to optimize their size, zeta potential, polydispersity index and encapsulation efficiency. Furthermore, these nano-vesicles were compared to a conventional miconazole-based commercially available cream to determine potential improvements via permeation through the stratum corneum, cytotoxicity, and antifungal capabilities. Our results found that the vesicle size was within the nano range (~300 nm), with moderate polydispersity and stability. When compared with the commercially available cream, Actavis, as well as free miconazole, the miconazole nano-vesicle formulation displayed enhanced fungal inhibition by a factor of three or more when compared to free miconazole. Furthermore, with smaller nanoparticle (NP) sizes, higher percentages of miconazole may be delivered, further enhancing the efficacy of miconazole’s antifungal capability. Cytotoxicity studies conducted with human dermal fibroblast cells confirm its biosafety and biocompatibility, as cell survival rate was observed to be twofold higher in nano-vesicle formulation than free miconazole. This formulation has the potential to treat fungal infections through increasing the retention time in the skin, improving the treatment approach, and by enhancing the efficacy via the use of nano-vesicles. Full article
(This article belongs to the Special Issue Drug Delivery by Soft Matter)
Show Figures

Figure 1

Back to TopTop